Neurogene
Dr. Albanis has more than 10 years of pharmaceutical and biotechnology industry experience, serving in roles of increasing responsibility at Novartis, Pharmasset, and Intercept Pharmaceuticals. Dr. Albanis is deeply motivated by a desire to improve patient care, and she regularly recites the mantra “patients are waiting” in an effort to instill a culture of urgency to accelerate development of treatments to patients in need. Most recently, she served as the Global Medical Lead of NASH at Intercept, where she was responsible for clinical development activities related to the company’s flagship Phase III clinical program, which included the largest clinical trial program for NASH. Dr. Albanis has also held positions in medical affairs, corporate strategy, and Phase I-IV clinical development. Dr. Albanis received her medical degree from the Mount Sinai School of Medicine, and completed her Internal Medicine, Gastroenterology and Hepatology training at the Mount Sinai Medical Center. During her tenure, she worked as a physician-scientist focused on grant-supported translational research in hepatic fibrosis while also managing advanced, decompensated hepatology patients in her practice. She remains on faculty at the Mount Sinai School of Medicine.
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.